So it's interesting that we are tracking the genetics of the patients prior to initiation of the medication. I find it interesting that in this n=72 patient trial, there were what 5 with the haplotype. That seems like a lot.

You are saying there may be even more that express increased CCR5 on the surfaces of their cells.

Possibly, we need to assess for the quantity of CCR5 surface expression and decide to give either 700 for those with higher CCR4 surface expression and give 350mg for normal CCR5 surface expression?